The future of chimerism monitoring is here!

Detection of Microchimerism: Achieves accurate results with sensitivity to >0.05%
Comprehensive Coverage: Utilises 24 population-independent InDel markers
Simple, efficient workflow and next-day results
Simplified Analysis: Advyser software completes the CE-IVD (IVDR-compliant) workflow, simplifying chimerism assessment with longitudinal tracking and flexible data presentation.

Get in touch with the VH Bio team to arrange a demonstration and have your questions answered.

"*" indicates required fields

Microchimerism Matters: Advancing HSCT Monitoring Through NGS [White Paper]
Minority Report: Why detecting microchimerism can make the biggest difference
Whitepaper: The role of chimerism following hematopoietic stem cell transplantation
“With its innovative design, the One Lambda Devyser Chimerism NGS assay offers a reliable, streamlined workflow designed specifically for chimerism monitoring. Compared to competitor NGS alternatives, this assay has the highest sensitivity (0.05%), lowest hands-on time (45 minutes), and is the only one to offer flexibility to the lab; the Chimerism library can be pooled with other One Lambda Devyser NGS workflows including HLA typing (AllType FASTplex) or donor-derived cell-free DNA monitoring (Accept cfDNA) on the same sequencing run.”
Read more: The Next Generation of Post-Transplant Chimerism Monitoring
Brochure: Improving chimerism measurement in post-transplant patient monitoring
Webinar: Reorienting and Recalibrating: NGS Chimerism Monitoring Post HSCT
Dr. Arthi Anand, H&I Lab Director at North West London Pathology and Consultant Clinical Scientist in H&I, NHS, shares insights from her research in chimerism testing, focusing on the impact of sensitivity on chimerism monitoring, detection, early signalling of disease relapse and the interpretation of chimerism numerical values.

With unmatched sensitivity, specificity, and ease of use, the One Lambda Devyser Chimerism NGS Assay allows transplant teams to detect relapse and rejection earlier and monitor against graft rejection more effectively.